TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23299470

Group type: EXPERIMENTAL
Intervention: High-resolution imaging techniques (AOSLO and SD-OCT)
Number of subjects: 11
Study: 23299770

Group type: EXPERIMENTAL
Intervention: CF102 (1, 5, and 25 mg BID)
Number of subjects: 18
Study: 23300829

Group type: EXPERIMENTAL
Intervention: (18)F-DPA-714 PET imaging in ALS patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy controls (matched for age)
Number of subjects: 10
Study: 23302513

Group type: EXPERIMENTAL
Intervention: Hatha yoga classes (2 weekly 60-minute sessions for 32 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Crescent pose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chair pose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Warrior II pose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: One-legged Balance pose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Side Stretch pose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tree pose
Number of subjects: 20
Study: 23303141

Group type: EXPERIMENTAL
Intervention: Chemoradiation and surgery
Number of subjects: 153
Study: 23303450

Group type: EXPERIMENTAL
Intervention: IL-6•IL-6Rα stimulation in HSFs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: STAT3 peptide inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knockdown of STAT3 by small interfering RNA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 23303512

Group type: EXPERIMENTAL
Intervention: Individual Burden of Illness Index for Depression (IBI-D) after 12-week citalopram treatment
Number of subjects: 2280

Group type: EXPERIMENTAL
Intervention: Changes in IBI-D for patients with abnormal QOL and/or functioning
Number of subjects: 2280

Group type: EXPERIMENTAL
Intervention: Changes in symptom severity (Quick Inventory of Depressive Symptomatology-Self Report)
Number of subjects: 2280
Study: 23303852

Group type: EXPERIMENTAL
Intervention: HIV+ patients
Number of subjects: 200

Group type: COMPARATOR
Intervention: HIV- controls
Number of subjects: 200
Study: 23305037

Group type: EXPERIMENTAL
Intervention: Glimepiride treatment (1 mg/d, titrated to 2 mg/d and 4 mg/d)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Glimepiride treatment
Number of subjects: 391
Study: 23305356

Group type: EXPERIMENTAL
Intervention: Patients with DM
Number of subjects: 2

Group type: COMPARATOR
Intervention: Patients without DM
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: TNFα increase immediately after stent implantation
Number of subjects: 2
Study: 23305475

Group type: EXPERIMENTAL
Intervention: Insulin analogues (insulin aspart, insulin detemir, biphasic insulin aspart 30)
Number of subjects: 10704
Study: 23305732

Group type: EXPERIMENTAL
Intervention: PET imaging on day 7 of induction
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: GEP high-risk designation
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Presence of > 3 focal lesions on day 7 PET follow-up
Number of subjects: 302
Study: 23305860

Group type: EXPERIMENTAL
Intervention: AF knowledge scale
Number of subjects: 529
Study: 23305955

Group type: EXPERIMENTAL
Intervention: NFKD
Number of subjects: 57
Study: 23306324

Group type: EXPERIMENTAL
Intervention: Definite Fabry disease diagnosed in 0.5% of patients (n=27)
Number of subjects: 5023

Group type: EXPERIMENTAL
Intervention: Probable Fabry disease diagnosed in additional 18 patients
Number of subjects: 5023

Group type: EXPERIMENTAL
Intervention: Silent infarcts on MRI
Number of subjects: 5023

Group type: EXPERIMENTAL
Intervention: Common causes of ischemic stroke
Number of subjects: 5023

Group type: EXPERIMENTAL
Intervention: Prevalence of classical risk factors
Number of subjects: 5023
Study: 23306540

Group type: EXPERIMENTAL
Intervention: Any history of donor smoking
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: FiO2 during allograft reperfusion
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Single lung transplant
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Use of cardiopulmonary bypass
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Overweight recipient body mass index
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Obese recipient body mass index
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Preoperative sarcoidosis
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Preoperative pulmonary arterial hypertension
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Mean pulmonary artery pressure
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Grade 3 PGD
Number of subjects: 1255
Study: 23307503

Group type: EXPERIMENTAL
Intervention: Physical activity (measured with accelerometers and self-report)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Higher total steps/day, higher PAEE, higher minutes of MPA/VPA, and higher PASE score
Number of subjects: 160
Study: 23307766

Group type: EXPERIMENTAL
Intervention: Antivirals administered to 1041 (58%) patients; treatment was at the physician's discretion.
Number of subjects: 1799

Group type: EXPERIMENTAL
Intervention: Oseltamivir resistance detected in 19 patients postbaseline (17 H1N1pdm2009 [H275Y]; 2 H3N2 [R292K]).
Number of subjects: 1799

Group type: EXPERIMENTAL
Intervention: All seasonal H1N1 strains were genotypically (H275Y) and phenotypically resistant to oseltamivir.
Number of subjects: 1799

Group type: EXPERIMENTAL
Intervention: Mutation-specific (MS) RT-PCR detected resistance to oseltamivir in 19 patients postbaseline.
Number of subjects: 1799

Group type: EXPERIMENTAL
Intervention: No emergent resistance was found in influenza B infections.
Number of subjects: 1799
Study: 23307953

Group type: EXPERIMENTAL
Intervention: Oxygen treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ambient air or pure oxygen-enriched air (without oxygen supplementation)
Number of subjects: 16
Study: 23308140

Group type: EXPERIMENTAL
Intervention: FDG SUVmax <6.6
Number of subjects: 40
Study: 23311614

Group type: EXPERIMENTAL
Intervention: Current smokers (AA females)
Number of subjects: 56466

Group type: COMPARATOR
Intervention: Former/never smokers (AA females)
Number of subjects: 56466

Group type: EXPERIMENTAL
Intervention: Current smokers (EA females)
Number of subjects: 56466

Group type: COMPARATOR
Intervention: Former/never smokers (EA females)
Number of subjects: 56466
Study: 23311764

Group type: EXPERIMENTAL
Intervention: Cord blood concentrations of ACTH, cortisol, fT3, and epinephrine in infants developing TTN
Number of subjects: 2

Group type: COMPARATOR
Intervention: Comparison group without respiratory distress
Number of subjects: 2
Study: 23312124

Group type: EXPERIMENTAL
Intervention: Δ melatonin concentration at 1 hour after the operation
Number of subjects: 40
Study: 23312922

Group type: EXPERIMENTAL
Intervention: Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 67
Study: 23313183

Group type: EXPERIMENTAL
Intervention: Patients' estimated maximum walking distance (MWD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Corridor maximum walking distance (MWD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Treadmill maximum walking distance (MWD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients' estimated MWD vs. corridor MWD
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients' estimated MWD vs. treadmill MWD
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients' estimated MWD vs. WIQ total score
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients' estimated MWD vs. WIQ distance score
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Corridor MWD vs. WIQ distance score
Number of subjects: 60
Study: 23313225

Group type: EXPERIMENTAL
Intervention: Serum hVEGF concentration measured 24 hours after admission
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: First measurement of serum hVEGF concentration
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Second measurement of serum hVEGF concentration
Number of subjects: 104
Study: 23314403

Group type: EXPERIMENTAL
Intervention: Older group (age > 50)
Number of subjects: 79

Group type: COMPARATOR
Intervention: NP-impaired group
Number of subjects: 79
Study: 23314553

Group type: EXPERIMENTAL
Intervention: Copeptin ultra-sensitive (copeptin-us) ≥14 pmol/L and hs-cTnT ≥0.014 µg/L
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Copeptin ultra-sensitive (copeptin-us) <14 pmol/L and hs-cTnT <0.014 µg/L
Number of subjects: 306

Group type: COMPARATOR
Intervention: hs-cTnT ≥0.014 µg/L alone
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Copeptin ultra-sensitive (copeptin-us) ≥14 pmol/L added to hs-cTnT
Number of subjects: 306
Study: 23315320

Group type: EXPERIMENTAL
Intervention: BDG and PCR assays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonculture tests (Mannan/anti-mannan IgG, β-D-glucan, PCR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonculture tests
Number of subjects: 0
Study: 23315343

Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (75-325 mg)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid experienced patients
Number of subjects: 340

Group type: COMPARATOR
Intervention: Low-dose acetylsalicylic acid naïve patients
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 340
Study: 23315371

Group type: EXPERIMENTAL
Intervention: HeartMate II devices (86 patients, 57%)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Not applicable (no control group mentioned)
Number of subjects: 150
Study: 23315599

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 60
Study: 23315905

Group type: EXPERIMENTAL
Intervention: Deficient 25(OH)D levels (<30 nmol/L)
Number of subjects: 4418

Group type: EXPERIMENTAL
Intervention: Inadequate 25(OH)D levels (30-49.9 nmol/L)
Number of subjects: 4418

Group type: EXPERIMENTAL
Intervention: High 25(OH)D levels (>100 nmol/L)
Number of subjects: 4418
Study: 23316287

Group type: EXPERIMENTAL
Intervention: Symptomatic lesions
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Symptomatic plaques
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Symptomatic patients
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Human aortic smooth muscle cell culture stimulated by TNF-α
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Human aortic smooth muscle cell culture stimulated by lipopolysaccharide
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Human aortic smooth muscle cell culture stimulated by lipoteichoic acid
Number of subjects: 78
Study: 23316326

Group type: EXPERIMENTAL
Intervention: Increased plasma fibulin-1 levels
Number of subjects: 125
Study: 23316779

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of CA4P at a dose of 27 or 36 mg/m2 for 4 consecutive weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of CA4P
Number of subjects: 8
Study: 23318482

Group type: EXPERIMENTAL
Intervention: Lesogaberan (AZD3355) as an add-on to PPI therapy
Number of subjects: 661

Group type: COMPARATOR
Intervention: PPI therapy
Number of subjects: 661
Study: 23320604

Group type: EXPERIMENTAL
Intervention: Low dose [90Y-DOTA]-TOC (median: 2.4 GBq/cycle)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Intermediate dose [90Y-DOTA]-TOC (median: 3.3 GBq/cycle)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: High dose [90Y-DOTA]-TOC (median: 6.7 GBq/cycle)
Number of subjects: 359
Study: 23320866

Group type: EXPERIMENTAL
Intervention: Overweight children
Number of subjects: 151

Group type: COMPARATOR
Intervention: Normal weight children
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Both groups (overweight and normal weight)
Number of subjects: 151
Study: 23320927

Group type: EXPERIMENTAL
Intervention: huKS-IL2 (3.0 mg/m2 IV continuous infusion over 4 hours on days 2, 3, and 4) with cyclophosphamide (300 mg/m2 on day 1)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: huKS-IL2 (various doses) with cyclophosphamide (300 mg/m2)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: huKS-IL2 with cyclophosphamide
Number of subjects: 27
Study: 23321252

Group type: EXPERIMENTAL
Intervention: YM155 alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of YM155 and alemtuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alemtuzumab alone
Number of subjects: 0
Study: 23321258

Group type: EXPERIMENTAL
Intervention: Hyperdiploidy >50 chromosomes (HD>50)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Modal number of chromosomes (MNC) groups: 51-53, 54-57, 58-66
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: DNA index (DI) subgroups: < 1.16, ≥1.16-<1.24, ≥1.24
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Karyotype assessment for patients with 58-66 chromosomes
Number of subjects: 541
Study: 23321489

Group type: EXPERIMENTAL
Intervention: In vitro fertilisation (IVF)
Number of subjects: 23498

Group type: COMPARATOR
Intervention: Natural pregnancies
Number of subjects: 23498
Study: 23321953

Group type: EXPERIMENTAL
Intervention: RAD001 (everolimus) 70 mg administered orally on days 1 and 7 of a 3+7 daunorubicin+cytarabine chemotherapy regimen
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: RAD001 (everolimus) 70 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: RAD001 (everolimus)
Number of subjects: 28
Study: 23324207

Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical model for estimation and outlier detection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Center characteristics (number of subjects enrolled, geographical location, learning over time, nitrous oxide, temporary clipping use)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subject and disease characteristics
Number of subjects: 0
Study: 23324524

Group type: EXPERIMENTAL
Intervention: Glycerol phenylbutyrate (GPB)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sodium phenylbutyrate (NaPBA)
Number of subjects: 15
Study: 23325011

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 23325012

Group type: EXPERIMENTAL
Intervention: Once-monthly pegylated epoetin Beta
Number of subjects: 0

Group type: COMPARATOR
Intervention: Darbepoetin alfa every two weeks
Number of subjects: 0
Study: 23325028

Group type: EXPERIMENTAL
Intervention: Directed media recruitment approach
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: General media recruitment approach
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Collaborations with support groups/interest groups
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Local free advertising resources (Craigslist and Backpage)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Physician outreach
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Internet-based approaches
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Referrals from study participants and screenees
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall multipronged recruitment approach
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall recruitment model
Number of subjects: 50
Study: 23325073

Group type: EXPERIMENTAL
Intervention: ESRD with NGT
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: ESRD with IGT
Number of subjects: 31

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: ESRD groups (NGT and IGT)
Number of subjects: 31
Study: 23325902

Group type: EXPERIMENTAL
Intervention: Everolimus (oral), starting at 3 mg/m2 per day, titrated to achieve trough concentrations of 5-15 ng/mL.
Number of subjects: 28
Study: 23325915

Group type: EXPERIMENTAL
Intervention: 5 mL of 2% nonoxynol-9 (N-9) gel
Number of subjects: 10

Group type: COMPARATOR
Intervention: 5 mL of Normosol-R fluid alone (negative control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5 mL of Normosol-R with coital simulation and sigmoidoscopic biopsy (CS + BX)
Number of subjects: 10
Study: 23325920

Group type: EXPERIMENTAL
Intervention: L-lysine from cooked white rice (CWR) at doses of 10, 15, and 19 mg·kg(-1)·d(-1)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: L-lysine from oven-browned cooked rice at a dose of 19 mg·kg(-1)·d(-1)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Reference protein (crystalline AA mixture patterned after egg protein)
Number of subjects: 5
Study: 23326928

Group type: EXPERIMENTAL
Intervention: Once daily insulin detemir
Number of subjects: 1671
Study: 23327295

Group type: EXPERIMENTAL
Intervention: Haloperidol prophylaxis (1 mg/8 h)
Number of subjects: 177
Study: 23327629

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 18630

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18630
Study: 23328269

Group type: EXPERIMENTAL
Intervention: Continuation maintenance pemetrexed therapy plus best supportive care (BSC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 0
Study: 23328340

Group type: EXPERIMENTAL
Intervention: Surgical side sensory dysfunction
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dynamic sensory mapping on day 1
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dynamic sensory mapping on day 2
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Comparison of areas on surgical vs nonsurgical side
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Test-retest assessments
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Presence of mirror pain
Number of subjects: 14
Study: 23329066

Group type: EXPERIMENTAL
Intervention: AZD4877 25 mg administered once-weekly for 3 weeks of each 4-week cycle until disease progression, death, unacceptable toxicity or withdrawal
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: AZD4877 25 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: AZD4877 Cmax on days 1 and 8
Number of subjects: 39
Study: 23329150

Group type: EXPERIMENTAL
Intervention: Normal vitamin D levels
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Low vitamin D levels
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Mild renal insufficiency with low vitamin D levels
Number of subjects: 110
Study: 23331449

Group type: COMPARATOR
Intervention: Physician-directed intervention
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Enhanced intervention (physician plus patient activation)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 1000
Study: 23331498

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23331739

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% ointment once daily for 12 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% ointment continued in open label extension for relapsing patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% ointment for perineal disease
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% ointment overall safety
Number of subjects: 20
Study: 23332165

Group type: EXPERIMENTAL
Intervention: Drug-eluting absorbable metal scaffold (DREAMS)
Number of subjects: 46
Study: 23332982

Group type: EXPERIMENTAL
Intervention: INCRAFT endograft
Number of subjects: 60
Study: 23333188

Group type: EXPERIMENTAL
Intervention: 3D ECV by cardiac CT
Number of subjects: 24
Study: 23333219

Group type: EXPERIMENTAL
Intervention: TNF-α antagonists (infliximab, etanercept, adalimumab)
Number of subjects: 34
Study: 23335740

Group type: EXPERIMENTAL
Intervention: Caspofungin 70 mg QD
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Caspofungin 100 mg QD
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Caspofungin 150 mg QD
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Caspofungin 200 mg QD
Number of subjects: 46
Study: 23337727

Group type: EXPERIMENTAL
Intervention: CYP21A2 mutation group null
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: CYP21A2 mutation group C
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: CYP21A2 mutation groups with more severe genotypes
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: CYP21A2 mutation groups
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Classic CAH and women with nonclassic CAH
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Adults with CAH
Number of subjects: 153
Study: 23338490

Group type: EXPERIMENTAL
Intervention: Mind-Body Bridging (MBB)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sleep Hygiene Education (SHE)
Number of subjects: 57
Study: 23339555

Group type: EXPERIMENTAL
Intervention: Quartet LV lead pacing from 10 vectors
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Pacing from additional LV lead pacing vectors
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Reprogramming pacing output
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Reprogramming to pace from additional vectors and reprogramming pacing output
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Reprogramming to pace from additional vectors alone
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Overall performance of Quartet LV lead
Number of subjects: 170
Study: 23339757

Group type: EXPERIMENTAL
Intervention: Intervention group (multi-center intervention study targeting family diabetes management)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 340
Study: 23340184

Group type: EXPERIMENTAL
Intervention: Visible cerebral NIRS oximetry with pre-specified treatment guidelines
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard care with blinded NIRS-monitoring
Number of subjects: 10
Study: 23340186

Group type: EXPERIMENTAL
Intervention: Direct patient contact
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Indirect patient care
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Communication with other staff
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Documentation of work
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Transport
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Personal time
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Other activities
Number of subjects: 9